Compounds > adenosine-5--(n-ethylcarboxamide)

adenosine-5--(n-ethylcarboxamide) and Thrombosis

adenosine-5--(n-ethylcarboxamide) has been researched along with Thrombosis* in 1 studies

Other Studies

1 other study(ies) available for adenosine-5--(n-ethylcarboxamide) and Thrombosis

Article	Year
Adenosine Receptor Agonist HE-NECA Enhances Antithrombotic Activities of Cangrelor and Prasugrel in vivo by Decreasing of Fibrinogen Density in Thrombus. International journal of molecular sciences, 2021, Mar-17, Volume: 22, Issue:6 Blood platelets' adenosine receptors (AR) are considered to be a new target for the anti-platelet therapy. This idea is based on in vitro studies which show that signaling mediated by these receptors leads to a decreased platelet response to activating stimuli. In vivo evidence for the antithrombotic activity of AR agonists published to date were limited, however, to the usage of relatively high doses given in bolus. The present study was aimed at verifying if these substances used in lower doses in combination with inhibitors of P2Y Topics: Adenosine Monophosphate; Adenosine-5'-(N-ethylcarboxamide); Adult; Animals; Antithrombins; Blood Pressure; Blood-Brain Barrier; Chlorides; Diastole; Female; Ferric Compounds; Fibrinogen; Humans; Laser-Doppler Flowmetry; Male; Mice, Inbred C57BL; Permeability; Platelet Activation; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P1 Receptor Agonists; Purinergic P2Y Receptor Antagonists; Systole; Thrombosis	2021

Article

Year

Adenosine Receptor Agonist HE-NECA Enhances Antithrombotic Activities of Cangrelor and Prasugrel in vivo by Decreasing of Fibrinogen Density in Thrombus.

International journal of molecular sciences, 2021, Mar-17, Volume: 22, Issue:6

Blood platelets' adenosine receptors (AR) are considered to be a new target for the anti-platelet therapy. This idea is based on in vitro studies which show that signaling mediated by these receptors leads to a decreased platelet response to activating stimuli. In vivo evidence for the antithrombotic activity of AR agonists published to date were limited, however, to the usage of relatively high doses given in bolus. The present study was aimed at verifying if these substances used in lower doses in combination with inhibitors of P2Y

Topics: Adenosine Monophosphate; Adenosine-5'-(N-ethylcarboxamide); Adult; Animals; Antithrombins; Blood Pressure; Blood-Brain Barrier; Chlorides; Diastole; Female; Ferric Compounds; Fibrinogen; Humans; Laser-Doppler Flowmetry; Male; Mice, Inbred C57BL; Permeability; Platelet Activation; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P1 Receptor Agonists; Purinergic P2Y Receptor Antagonists; Systole; Thrombosis

2021